BPMC News and Press, Blueprint Medicines Corporation From 12/01/20

Blueprint Medicines Announces FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer CAMBRIDGE, Mass. , Dec. 1, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (N...

Blueprint Medicines To Present Broad Range of Data Reinforcing Commitment to Advance Patient Care in Systemic Mastocytosis at 62nd ASH Annual Meeting and Exposition PR Newswire CAMBRIDGE, Mass., Nov. 23, 2020 CAMBRIDGE, Mass. , Nov. 23, 2020 /PRNewswire/ -- B...

Blueprint Medicines Corporation (BPMC) Q3 2020 Earnings Conference Call Oct 29, 2020 8:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - COO Mike Landsittel - CFO Conference Call Participants Marc Frahm - Cowen and Company Reni Benjamin - JMP ...

Blueprint Medicines  (BPMC): Q3 GAAP EPS of $11.16 beats by $1.80.Revenue of $745.12M (+8052.3% Y/Y) beats by $117.7M.Shares -0.37% PM.Press Release For further details see: Blueprint Medicines  EPS beats by $1.80, beats on revenue

Blueprint Medicines Reports Third Quarter 2020 Financial Results -- Obtained FDA approval and launched GAVRETO™ for RET fusion-positive non-small cell lung cancer -- -- Announced top-line EXPLORER and PATHFINDER data for AVYAKIT™ in advanced systemic mastocytos...

Blueprint Medicines  (NASDAQ:BPMC) is scheduled to announce Q3 earnings results on Thursday, October 29th, before market open.The consensus EPS Estimate is $9.36 (+585.0% Y/Y).Over the last 1 year, BPMC has beaten EPS estimates 25% of the time and has beaten revenue estimates 25% of the ...

Blueprint Medicines to Report Third Quarter 2020 Financial Results on Thursday, October 29, 2020 PR Newswire CAMBRIDGE, Mass., Oct. 22, 2020 CAMBRIDGE, Mass. , Oct. 22, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision ther...

The biotech industry has had a strong year due to search for a COVID vaccine. But there is one area of the industry that a consensus of hedge fund managers think is the future. Here are the top biotech stocks favored by hedge fund managers: Seattle Genetics (SGEN), Fate Therapeutics (FATE), a...

Blueprint gets European Union nod for Ayvakyt. Aquestive receives CRL for seizure clusters treatment Libervant. PMV Pharma makes impressive IPO debut, stock soars. For further details see: Blueprint European Approval, And Other News: The Good, Bad And Ugly Of Biopharma ...

As expected, the European Commission approves Blueprint Medicines' ([[BPMC]] -0.7%) Ayvakyt (avapritinib) as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumors ((GIST)) harboring the platelet-derived growth factor receptor alpha ((P...